Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Mid Cap
Health Score : 8.38Glaxosmithkline Pharmaceuticals Ltd. shows very strong financial health, primarily driven by exceptional profitability and robust growth. The company is extremely good at turning revenue into profit and provides excellent returns on the money invested in it. Its long-term stability is outstanding, as it operates with almost no debt, making it very resilient. The company is also expanding its earnings and market presence at an impressive rate. However, its efficiency in day-to-day operations presents a mixed picture. While it collects payments quickly, it is slower in selling its inventory and does not use its total capital base as effectively to generate sales. Its ability to cover short-term bills is adequate but shows some areas of pressure. The future outlook is positive, supported by strong growth and profitability, though attention to operational efficiency and investment in future assets are notable aspects of its financial story.
Health Score : 8.38Glaxosmithkline Pharmaceuticals Ltd. shows very strong financial health, primarily driven by exceptional profitability and robust growth. The company is extremely good at turning revenue into profit and provides excellent returns on the money invested in it. Its long-term stability is outstanding, as it operates with almost no debt, making it very resilient. The company is also expanding its earnings and market presence at an impressive rate. However, its efficiency in day-to-day operations presents a mixed picture. While it collects payments quickly, it is slower in selling its inventory and does not use its total capital base as effectively to generate sales. Its ability to cover short-term bills is adequate but shows some areas of pressure. The future outlook is positive, supported by strong growth and profitability, though attention to operational efficiency and investment in future assets are notable aspects of its financial story.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
50.16
Industry Median
30.91
Mid Cap Median
44.19
P/E RATIO
49.00
P/B RATIO
22.36
Industry Median
3.69
Mid Cap Median
6.64
P/S RATIO
14.52
Industry Median
3.74
Mid Cap Median
6.84
Others
PEG RATIO
0.00
EV/EBITDA RATIO
36.70
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2996.1 as on Sep 1, 2026.
Growth Score : 10.00The company is on an excellent growth trajectory. Despite some volatility in the past, its recent and projected performance shows strong and consistent expansion across key areas. Revenues, operating profits, and earnings per share are all growing robustly. This indicates strong market demand, effective management, and a positive outlook for the future. This comprehensive growth is a major strength and signals that the company is successfully increasing its size and value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 12.03 | -0.79 | 6.21 | 8.54 | 1.95 |
| Operating Profit Growth Rate | 27.42 | 5.51 | 13.06 | 29.7 | 11.03 |
| Earnings Per Share (EPS) Growth | 373.23 | -63.96 | -3.38 | 57.19 | 11.69 |
| Asset Growth Rate | 48.73 | -28.19 | 6.91 | 15.49 | 5.26 |
| Net Income Growth Rate | 373.46 | -63.95 | -3.44 | 57.29 | 11.64 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | ABBOTINDIA | 8.68 | 35.78 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | GLAXO | 8.38 | 49.00 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | JBCHEPHARM | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | ALKEM | 8.08 | 27.53 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | GLAND | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 6 | NEULANDLAB | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 7 | AJANTPHARM | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | APLLTD | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 9 | EMCURE | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 10 | SYNGENE | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 11 | ERIS | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 12 | LAURUSLABS | 7.10 | 113.10 | Neutral | 1778.00 | 13.71 | 890.00 |
| 13 | GLENMARK | 6.36 | 51.19 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 14 | IPCALAB | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 15 | PPLPHARMA | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 16 | WOCKPHARMA | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 17 | PFIZER | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is a leading pharmaceutical company in India, a subsidiary of the global GSK Plc. It focuses on manufacturing, distributing, and trading a broad portfolio of pharmaceutical products and vaccines across key therapeutic areas, maintaining a significant presence in the Indian healthcare market.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Glaxosmithkline Pharmaceuticals Ltd's P/E ratio (TTM) is 50.16, compared to the industry median of 30.91 and large cap median of 44.19.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Glaxosmithkline Pharmaceuticals Ltd's P/B ratio is 22.36, compared to the industry median of 3.69 and large cap median of 6.64.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Glaxosmithkline Pharmaceuticals Ltd's P/S ratio is 14.52, compared to the industry median of 3.74 and large cap median of 6.84.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Glaxosmithkline Pharmaceuticals Ltd's PEG ratio is 1.50.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Glaxosmithkline Pharmaceuticals Ltd's EV/EBITDA ratio is 36.70.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Glaxosmithkline Pharmaceuticals Ltd's ROE is 45.70%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Glaxosmithkline Pharmaceuticals Ltd's ROA is 30.27%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Glaxosmithkline Pharmaceuticals Ltd's ROCE is 65%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Glaxosmithkline Pharmaceuticals Ltd's operating margin is 34.25%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Glaxosmithkline Pharmaceuticals Ltd's net margin is 27.11%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Glaxosmithkline Pharmaceuticals Ltd's current ratio is 1.29.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Glaxosmithkline Pharmaceuticals Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Glaxosmithkline Pharmaceuticals Ltd's interest coverage ratio is 469.67.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Glaxosmithkline Pharmaceuticals Ltd's DPS is ₹56.87.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Glaxosmithkline Pharmaceuticals Ltd's EPS is 11.69.
(Source line: "Ratios as of 21 Sept 2026, based on last traded price of ₹2996.10. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1924 (as H. J. Foster & Co. Ltd.)
Headquarters: Mumbai, Maharashtra
Core Offerings: Prescription Medicines, Vaccines, Specialty Care Products, Anti-infectives, Respiratory products
Stock Listing: NSE (GLAXO), BSE (500660)
Promoter: GlaxoSmithKline Plc
GlaxoSmithKline Pharmaceuticals Ltd was incorporated in 1924 as H. J. Foster & Co. Ltd. It later became Glaxo Laboratories (India) Ltd., growing into a significant player in the Indian pharmaceutical sector. Following global mergers, it eventually became part of GlaxoSmithKline Plc. Today, it continues to be a major manufacturer and marketer of pharmaceuticals and vaccines, serving a wide range of patient needs across India.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals (including Vaccines) | 100% | N/A (segment-wise EBITDA not separately reported) |
Pharmaceuticals: Offers a broad portfolio of prescription medicines across various therapeutic areas such as respiratory, dermatology, anti-infectives, cardiovascular, and specialty care including oncology.
Vaccines: A significant provider of vaccines in India, offering immunization solutions against diseases like hepatitis, diphtheria, tetanus, pertussis, polio, influenza, and rotavirus.
Sridhar Venkatesh (Managing Director & Vice President, Commercial Operations, India): An experienced pharmaceutical leader who joined GSK in 2011, holding various commercial and general management roles across different markets. R. Kannan (Chairman & Independent Director): A seasoned finance professional with extensive experience in leadership and governance roles across various companies.
No major subsidiaries reported.
Divestment of GlaxoSmithKline Consumer Healthcare Ltd. (a group entity) in 2020, which resulted in proceeds for GSK Pharma India for its stake in GlaxoSmithKline Asia Pvt. Ltd.
The Glaxosmithkline Pharmaceuticals Ltd share price today is ₹2996.10 on NSE (GLAXO), as of 22 Sept 2026.
As of 21 Sept 2026, Glaxosmithkline Pharmaceuticals Ltd share price is ₹2996.10, with previous close ₹2996.10. Today's range is ₹2996.10 to ₹2996.10. The 52-week range is ₹2088.10 to ₹3120.70.
As of today, Glaxosmithkline Pharmaceuticals Ltd's market cap is ₹55,487.77 crore (Large Cap).
Glaxosmithkline Pharmaceuticals Ltd's current P/E ratio is 50.16, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 37.
Glaxosmithkline Pharmaceuticals Ltd's current P/B ratio is 22.36.
Glaxosmithkline Pharmaceuticals Ltd's current dividend yield is 1.90%. Last dividend of ₹10.00 per share was declared on 20-Nov-2023.
Glaxosmithkline Pharmaceuticals Ltd's EPS (TTM) is ₹11.69.
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is a leading pharmaceutical company in India, a subsidiary of the global GSK Plc. It focuses on manufacturing, distributing, and trading a broad portfolio of pharmaceutical products and vaccines across key therapeutic areas, maintaining a significant presence in the Indian healthcare market.
Glaxosmithkline Pharmaceuticals Ltd is promoted by GlaxoSmithKline Plc, holding 75% as of 21 Sept 2026.
Glaxosmithkline Pharmaceuticals Ltd is listed on NSE (GLAXO) and BSE (500660). Its next quarterly results are expected on July/August 2024 (Q1 FY25).
Quick Ratios
